Cytochalasin H Inhibits Angiogenesis
ERK1/2
PI3K/AKT/P70S6K
angiogenesis
cytochalasin H (CyH)
hypoxia inducible factor-1α (HIF-1α)
mangrove
non-small cell lung cancer (NSCLC)
vascular endothelial growth factor (VEGF)
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
09
2018
accepted:
10
03
2019
entrez:
18
6
2019
pubmed:
18
6
2019
medline:
18
6
2019
Statut:
epublish
Résumé
Our previous study has demonstrated that cytochalasin H (CyH) isolated from mangrove-derived endophytic fungus induces apoptosis and inhibits migration in A549 non-small cell lung cancer (NSCLC) cells. In this study, we further explored the effect of CyH on angiogenesis in NSCLC cells and the underlying molecular mechanisms. A549 and H460 NSCLC cells were treated with different concentrations of CyH for 24 h. The effects of CyH on NSCLC angiogenesis
Identifiants
pubmed: 31205560
doi: 10.7150/jca.29933
pii: jcav10p1997
pmc: PMC6548170
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1997-2005Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Oncogene. 2000 Apr 20;19(17):2138-46
pubmed: 10815805
J Pharmacol Exp Ther. 2000 Aug;294(2):421-7
pubmed: 10900214
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
J Biol Chem. 2003 Sep 12;278(37):35501-7
pubmed: 12816951
Oncogene. 2004 Jan 8;23(1):192-200
pubmed: 14712224
J Clin Pathol. 2004 Jun;57(6):591-7
pubmed: 15166262
J Clin Pathol. 2005 Nov;58(11):1170-4
pubmed: 16254106
Nat Clin Pract Oncol. 2006 Dec;3(12):682-92
pubmed: 17139319
Int J Cancer. 2007 Nov 15;121(10):2225-32
pubmed: 17471564
Biochem Cell Biol. 2008 Jun;86(3):227-34
pubmed: 18523483
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biol Pharm Bull. 2011;34(6):850-5
pubmed: 21628883
Cancer Lett. 2011 Dec 8;311(2):160-70
pubmed: 21868151
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946
Biochem Soc Trans. 2012 Feb;40(1):139-46
pubmed: 22260680
Cancer Lett. 2012 Jul 28;320(2):130-7
pubmed: 22425960
Expert Opin Ther Targets. 2012 Apr;16(4):395-406
pubmed: 22439677
Cancer Chemother Pharmacol. 2013 Mar;71(3):713-25
pubmed: 23292117
Lancet. 2013 Aug 24;382(9893):709-19
pubmed: 23972814
Biol Pharm Bull. 2014;37(1):6-12
pubmed: 24172060
Mol Cancer. 2013 Nov 22;12:147
pubmed: 24261856
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
PLoS One. 2014 Jul 24;9(7):e103440
pubmed: 25058399
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97
pubmed: 25417232
Cell Oncol (Dordr). 2015 Apr;38(2):111-8
pubmed: 25561311
Int J Cancer. 2016 Jun 1;138(11):2549-61
pubmed: 26537995
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Oncol Lett. 2016 Feb;11(2):1242-1250
pubmed: 26893726
Oncol Lett. 2016 Mar;11(3):1738-1744
pubmed: 26998070
Front Microbiol. 2016 Aug 26;7:1307
pubmed: 27617005
Biomed Pharmacother. 2017 Jan;85:549-555
pubmed: 27889230
J Thorac Dis. 2016 Nov;8(11):3457-3463
pubmed: 28066627
Oncol Lett. 2017 May;13(5):2909-2914
pubmed: 28521397
Cell Oncol (Dordr). 2017 Jun;40(3):199-208
pubmed: 28534212
Oncotarget. 2017 Jul 28;8(49):85252-85262
pubmed: 29156717
Oncol Rep. 2018 Jun;39(6):2899-2905
pubmed: 29620283
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Cancer. 2018 Sep 8;9(19):3456-3466
pubmed: 30310502
Onco Targets Ther. 2018 Oct 17;11:6901-6909
pubmed: 30410348
Lab Invest. 1996 Jun;74(6):1105-15
pubmed: 8667614